Eli Lilly Revenue 2010-2023 | LLY
Eli Lilly annual/quarterly revenue history and growth rate from 2010 to 2023. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Eli Lilly revenue for the quarter ending December 31, 2023 was $9.353B, a 28.1% increase year-over-year.
- Eli Lilly revenue for the twelve months ending December 31, 2023 was $34.124B, a 19.56% increase year-over-year.
- Eli Lilly annual revenue for 2023 was $34.124B, a 19.56% increase from 2022.
- Eli Lilly annual revenue for 2022 was $28.541B, a 0.79% increase from 2021.
- Eli Lilly annual revenue for 2021 was $28.318B, a 15.4% increase from 2020.
Eli Lilly Annual Revenue
(Millions of US $) |
| 2023 |
$34,124 |
| 2022 |
$28,541 |
| 2021 |
$28,318 |
| 2020 |
$24,540 |
| 2019 |
$22,320 |
| 2018 |
$21,493 |
| 2017 |
$19,974 |
| 2016 |
$21,222 |
| 2015 |
$19,959 |
| 2014 |
$19,616 |
| 2013 |
$23,113 |
| 2012 |
$22,603 |
| 2011 |
$24,287 |
| 2010 |
$23,076 |
| 2009 |
$21,836 |
Eli Lilly Quarterly Revenue
(Millions of US $) |
| 2023-12-31 |
$9,353 |
| 2023-09-30 |
$9,499 |
| 2023-06-30 |
$8,312 |
| 2023-03-31 |
$6,960 |
| 2022-12-31 |
$7,302 |
| 2022-09-30 |
$6,942 |
| 2022-06-30 |
$6,488 |
| 2022-03-31 |
$7,810 |
| 2021-12-31 |
$8,000 |
| 2021-09-30 |
$6,773 |
| 2021-06-30 |
$6,740 |
| 2021-03-31 |
$6,806 |
| 2020-12-31 |
$7,440 |
| 2020-09-30 |
$5,741 |
| 2020-06-30 |
$5,499 |
| 2020-03-31 |
$5,860 |
| 2019-12-31 |
$6,114 |
| 2019-09-30 |
$5,477 |
| 2019-06-30 |
$5,637 |
| 2019-03-31 |
$5,092 |
| 2018-12-31 |
$5,638 |
| 2018-09-30 |
$5,307 |
| 2018-06-30 |
$5,585 |
| 2018-03-31 |
$4,964 |
| 2017-12-31 |
$3,263 |
| 2017-09-30 |
$5,658 |
| 2017-06-30 |
$5,824 |
| 2017-03-31 |
$5,228 |
| 2016-12-31 |
$5,761 |
| 2016-09-30 |
$5,192 |
| 2016-06-30 |
$5,405 |
| 2016-03-31 |
$4,865 |
| 2015-12-31 |
$5,376 |
| 2015-09-30 |
$4,960 |
| 2015-06-30 |
$4,979 |
| 2015-03-31 |
$4,645 |
| 2014-12-31 |
$5,121 |
| 2014-09-30 |
$4,876 |
| 2014-06-30 |
$4,936 |
| 2014-03-31 |
$4,683 |
| 2013-12-31 |
$5,809 |
| 2013-09-30 |
$5,773 |
| 2013-06-30 |
$5,930 |
| 2013-03-31 |
$5,602 |
| 2012-12-31 |
$5,957 |
| 2012-09-30 |
$5,443 |
| 2012-06-30 |
$5,601 |
| 2012-03-31 |
$5,602 |
| 2011-12-31 |
$6,047 |
| 2011-09-30 |
$6,148 |
| 2011-06-30 |
$6,253 |
| 2011-03-31 |
$5,839 |
| 2010-12-31 |
$6,187 |
| 2010-09-30 |
$5,655 |
| 2010-06-30 |
$5,749 |
| 2010-03-31 |
$5,486 |
| 2009-12-31 |
$5,934 |
| 2009-09-30 |
$5,562 |
| 2009-06-30 |
$5,293 |
| 2009-03-31 |
$5,047 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$708.528B |
$34.124B |
|
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
|
